Otsuka Pharmaceutical Co., Ltd. $4578.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-38
RECRUITING6
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO12%
Delay Index: of 8 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Otsuka Pharmaceutical Co., Ltd. on the live radar map → 📅 $4578.T readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| OPA-15406 NCT07173478 |
P3 | Not yet recruiting | Atopic Dermatitis (AD) | 156 | 2026-12 |
| OPA-15406 NCT07184645 |
P3 | Not yet recruiting | Atopic Dermatitis (AD) | 198 | 2027-02 |
| EB-1020 (Centanafadine) low dose NCT07086313 |
P2/3 | Recruiting | Attention-Deficit Hyperactivity Disorder(ADHD) | 315 | 2027-08 |
| EB-1020 (Centanafadine) low dose NCT07087327 |
P3 | Recruiting | Attention-Deficit Hyperactivity Disorder(ADHD) | 180 | 2027-08 |
| OPC-34712FUM/ Brexpiprazole fumarate NCT05325645 |
P3 | Recruiting | Acute Schizophrenia | 450 | 2027-09 (+29 mo) |
| EB-1020 (Centanafadine) 164.4 mg NCT06931080 |
P2/3 | Recruiting | Attention Deficit Hyperactivity Disorder (ADHD) | 630 | 2027-12 |
| EB-1020 (Centanafadine) 164.4 mg NCT06926829 |
P3 | Recruiting | Attention Deficit Hyperactivity Disorder (ADHD) | 180 | 2027-12 |
| SEP-363856 NCT07225712 |
P3 | Recruiting | Schizophrenia | 100 | 2028-03 |